Report of Foreign Issuer (6-k)
April 08 2019 - 3:53PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
6-K
Report
of Foreign Private Issuer
Pursuant
to Rule 13a-16 or 15d-16
under
the Securities Exchange Act of 1934
For
the month of: April 2019
Commission
file number: 001-36578
ENLIVEX
THERAPEUTICS LTD.
(Translation
of registrant’s name into English)
14
Einstein Street, Nes Ziona, Israel 7403618
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1): ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7): ☐
On
April 3, 2019, Enlivex Therapeutics Ltd., a company organized under the laws of the State of Israel (the “
Company
”),
entered into a securities purchase agreement with a private investor (the “
Investor
”), pursuant to which, on
April 4, 2019, the Investor acquired, in a private transaction, an aggregate of 244,898 of the company’s ordinary shares
at a purchase price of $12.25 per share, providing gross proceeds to the Company of approximately $3.0 million (the “
Private
Placement
”).
The
ordinary shares of the Company issued pursuant to the Private Placement have not been registered under the Securities Act of 1933,
as amended (the “
Securities Act
”). The Company offered and sold such ordinary shares in reliance upon the exemptions
from registration contained in Section 4(a)(2) of the Securities Act and/or Regulation S promulgated thereunder.
This
Report on Form 6-K does not constitute an offer to sell, or the solicitation of an offer to buy, any securities and shall not
constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful.
This
Report on Form 6-K of the Company is incorporated by reference into the registration statements on Form S-8 (File No. 333-203114
and 333-210459) of the Company, filed with the Securities and Exchange Commission.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
Enlivex
Therapeutics Ltd.
|
|
(Registrant)
|
|
|
|
By:
|
/s/
Shai Novik
|
|
Name:
Title:
|
Shai
Novik
Executive Chairman
|
Date:
April 8, 2019
2
Enlivex Therapeutics (NASDAQ:ENLV)
Historical Stock Chart
From Jun 2024 to Jul 2024
Enlivex Therapeutics (NASDAQ:ENLV)
Historical Stock Chart
From Jul 2023 to Jul 2024